Jefferies reiterates Ventiv Health at buy

Ventiv Health was reiterated by Jefferies & Co. Inc. analyst David Windley at a buy rating and $30 price target after an announcement by the company that it expanded two of its largest contracts and added four new, small contracts that improve visibility. Ventiv provides outsourced sales, marketing and compliance services for the pharmaceutical industry. Shares of the Somerset, N.J., company were down 26 cents, or 1%, at $25.84 on volume of 603,858 shares versus the three-month running average of 546,008 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.